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Dietary Fructose: Implications for Dysregulation of Energy
Homeostasis and Lipid/Carbohydrate Metabolism
Peter J. Havel, DVM, PhD
Fructose intake and the prevalence of obesity have
both increased over the past two to three decades.
Compared with glucose, the hepatic metabolism of
fructose favors lipogenesis, which may contribute to
hyperlipidemia and obesity. Fructose does not in-
crease insulin and leptin or suppress ghrelin, which
suggests an endocrine mechanism by which it induces
a positive energy balance. This review examines the
available data on the effects of dietary fructose on
energy homeostasis and lipid/carbohydrate metabo-
lism. Recent publications, studies in human subjects,
and areas in which additional research is needed are
emphasized.
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INTRODUCTION
Recent review articles have focused on increased intake
of dietary fructose and its possible association with the
increased prevalence of obesity and obesity-related dis-
eases over past two to three decades.1,2 Potential meta-
bolic and endocrine mechanisms underlying the effects
of fructose consumption on energy balance and its rela-
tionship to weight gain and obesity have been proposed.
Compared with other carbohydrates, which are com-
posed primarily of glucose, the hepatic metabolism of
fructose favors lipogenesis, which in addition to inducing
hyperlipidemia, may contribute to weight gain and obe-
sity. Furthermore, there are distinct differences between
the effects of fructose and glucose on the secretion of
insulin, leptin, and ghrelin, which are key signals in-
volved in the long-term endocrine regulation of energy
balance and body adiposity.3,4
Despite a number of studies demonstrating that fruc-
tose feeding leads to weight gain and hyperlipidemia in
animals, and the epidemiological parallel between fruc-
tose intake and the marked increase in the proportion of
overweight and obesity, there is currently little in the
way of direct evidence linking these phenomena in hu-
mans. The goal of this review is to examine the currently
available data on the interaction of dietary fructose with
the endocrine and metabolic pathways involved in the
control of energy homeostasis and lipid metabolism,
emphasizing recently published studies and reviews and
studies conducted in humans. Areas in which further
research is needed are also discussed.
SOURCES AND INTAKE OF DIETARY
CARBOHYDRATE
Dietary Carbohydrate Intake
The National Academy of Sciences has recommended
that between 45% and 65% of energy be derived from
carbohydrates, 20% to 35% from fat, and 10% to 35%
from protein, with no more than 25% of total energy
from added sugars.5 Recommendations by the American
Heart Association6 and the American Diabetes Associa-
tion7 fall well within these broad guidelines: approxi-
mately 50% of energy from carbohydrate, 30% from fat,
and 20% from protein. There are two major, population-
based methodological approaches for estimating energy
and nutrient intakes. Food disappearance data reflect the
nationwide availability of foods and thus tend to over-
estimate consumption. In contrast, survey-based ap-
proaches that rely primarily on the ability of respondents
to recall categories and amounts of previous intake tend
to underestimate consumption but have the advantage of
estimating intake characteristics in distinct subsets of the
population. Results from the US Department of Agricul-
ture Continuing Survey of Food Intakes by Individuals
(CSFII) suggest that from 1994 to 1996, non-vegetarians
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consumed 50% of energy from carbohydrate, 33% from
fat, and 16% from protein, with 15% to 16% of energy
provided by added sugars. Data from the National Health
and Nutrition Survey (NHANES) as reported by the
Centers for Disease Control and Prevention (CDC)8
indicate that carbohydrate intake increased by about 62
g/d in women and by about 69 g/d in men between 1971
and 2000.
Added Sugar and Fructose Intake
In a detailed report published in 20039 defining and
interpreting the intake of sugars, the authors concluded
that there is sufficient lack of rigor in data collection for
added sugar intake to indicate that such estimates are
likely to be inaccurate. Recent reviews cite the average
per capita intake of added sugars from all sources based
on economic disappearance data (i.e., available supply)
to be approximately 64 kg per year in 1970 and approx-
imately 80 kg per year (218 g/d; 872 kcal/d) in 2000,
representing a 25% increase of added sweeteners over
the past three decades.1,2 These disappearance data most
certainly overestimate total consumption, but not neces-
sarily the proportional increase of added sugar intake.
Survey-based intake data from the 1994–1996 CSFII, as
analyzed by Bowman in 1999,10 indicated an average per
capita intake of added sugars of 79 g/d (316 kcal/d or
28.8 kg/year). This is certainly an underestimate of
actual consumption. Of interest in these analyses are the
top tertile of consumers, who derive about 27% of their
calories from added sugars, with an average intake of
137 g/d (548 kcal),10 and the top quintile of consumers
averaging 178 g/d (712 kcal/d).1
Although free fructose, along with free glucose and
sucrose, is present in significant quantities in fruits and
some vegetables, the largest single source of fructose in
the diet is added sugars consumed in desserts, candies,
and, most importantly, in soft drinks and other sweetened
beverages. The 1994–1996 CSFII data indicate that soft
drinks and fruit drinks provide about 43% of the calories
from added sugars. Disappearance data indicate that the
primary source of added sweeteners in the United States
is high-fructose corn syrup (HFCS),11 which is used to
sweeten the majority of beverages containing added
sugars.
There is a widespread misconception among the
public, and even some nutrition professionals, that HFCS
is composed entirely of fructose. However, the vast
majority of HFCS used in the US food supply is a
mixture of glucose and fructose, with the most com-
monly used formulations containing either 42% fructose
(HFCS-42) or 55% fructose (HFCS-55).12 In addition, an
increasing number of beverages are sweetened with con-
centrated fruit juices such as apple and white grape juice.
Interestingly, fruit juices vary widely in the amount of
fructose they contain, with apple juice containing 65% of
energy from fructose and orange juice only 40% to 45%.
Thus, apple juice and some juice-sweetened beverages
can contain more fructose on a percent-energy basis than
soft drinks sweetened with HFCS-42 or HFCS-55. Crys-
talline fructose of close to 100% purity is used to
sweeten some beverages and foods.13 While it is not
clear precisely how much crystalline fructose is currently
used in the food supply, its contribution to total fructose
intake compared with sucrose and HFCS would still
appear to be quite limited.
The replacement of sucrose with HFCS in soft
drinks can impact the ratio of fructose to glucose in the
diets of individuals, as HFCS-55 has a fructose-to-glu-
cose ratio of 1.22 and contains 10% more fructose by
weight than sucrose. Approximately 60% of the HFCS
used in the food supply is HFCS-55 and 40% is HFCS-
42.11 It appears from the combined use of sucrose,
HFCS-42, and HFCS-55 that fructose constitutes very
close to 50% of energy in added sweeteners.1 Therefore,
50% of the intake of added sweeteners discussed above
is likely to provide a reasonably close approximation of
total fructose intake. Accordingly, a conservative esti-
mate based on CSFII survey data is that the average
energy intake of fructose from added sugars is 7% to 8%.
Energy from added sugars plus the naturally occurring
sugars in fruit and fruit juices is over 12%. This estimate
is based on consumption of sweets/desserts, soft drinks,
fruit, and fruit juices.14 Food disappearance data indicate
that about 10% of the energy in the food supply is from
fructose contained in added sugars. This is quite close to
the 11.5% of energy value in the CFSII data from
1994–1998.
Thus, based on a 2000 kcal/d diet, average daily
fructose consumption would be approximately 60 g/d.
Again, these values are likely to underestimate actual
consumption due to selective underreporting of specific
foods and beverages.15 Because some age groups, such
as adolescent males, are heavy consumers of soft
drinks,16 and the top quintile of sugar users consume 2.2
times the average intake,1 certain segments of the pop-
ulation are likely to be consuming well over 100 g/d of
fructose from added sweeteners. For example, in one
study of over 1400 8th-grade adolescents, 32.4% of their
calorie intake was from added sugars, equivalent to 800
kcal/d (200 g/d), of which approximately one-half or
400 kcal/d (100 g/d) would be expected to be derived
from fructose.17
It is clear that whether disappearance data or survey
results are used, total fructose intake, along with total
energy and sweetener intake, has increased between the
1970s and the mid-1990s. The total amount of energy per
capita available in the food supply based on food disap-
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pearance data from the USDA increased by approxi-
mately 20% between 1975 and 2000, and total energy
intake from NHANES survey data was reported to in-
crease by 7% in men and 22% in women from 1971–
1974 to 1999–2000.8 Based on all available data, the
increase of total per capita fructose consumption over
these three decades is likely to be between 20% and 40%,
with a 25% increase representing a reasonable estimate.
SUGAR ABSORPTION
The principal sugars in the diet are glucose, fructose,
sucrose, lactose, and maltose.18 Maltose is a disaccharide
composed of two molecules of glucose that are hydro-
lyzed at the intestinal brush border by maltases. Lactose
is composed of one molecule of glucose and one mole-
cule of galactose. After hydrolysis by lactase, galactose
is converted to glucose in the process of absorption and
transport by enterocytes. Thus, the majority of the car-
bohydrate in milk and dairy products is metabolized as
glucose. Sucrose, which consists of one molecule of
glucose and one molecule of fructose, is hydrolyzed by
sucrase. Glucose, the product of starch (digested by
amylases) and maltose digestion, is rapidly absorbed via
a sodium-coupled co-transporter and arrives at the liver
via the portal circulation.
Fructose absorption and transport through entero-
cytes to the portal bloodstream is performed by a fruc-
tose-specific hexose transporter, GLUT5, that is primar-
ily expressed in the jejunum on both the brush border and
the basolateral enterocyte membranes.18 GLUT5 is also
expressed, but at relatively lower levels, in kidney, skel-
etal muscle, adipocytes, and glial cells. Consumption of
a large amount of pure fructose can exceed the capacity
of intestinal fructose absorption, resulting in diarrhea.
However, the consumption of glucose along with fruc-
tose, as it is usually consumed in beverages and with
meals, appears to enhance fructose absorption.19 In ad-
dition, fructose absorption increases during sustained
fructose consumption, suggesting adaptation to increased
fructose intake.
FRUCTOSE METABOLISM
Although GLUT5 fructose transporters are expressed at
low levels in a number of tissues, including skeletal
muscle and adipose tissue, the liver is by far the most
important site of fructose metabolism, which has impor-
tant effects on both lipid and carbohydrate metabolism.20
After absorption, ingested fructose arrives at the liver via
the portal vein. The liver efficiently takes up portal
fructose such that little escapes hepatic metabolism and
enters the systemic circulation after consumption of
moderate amounts of fructose. After ingestion of 1 g of
fructose per kilogram body weight, blood fructose levels
only increase to about 0.5 mmol/L. This is much less
than the increase of plasma glucose levels (by 10
mmol/L) in subjects with normal glucose tolerance after
a 75 g oral glucose tolerance test. The half-life of
fructose in the peripheral plasma after intravenous fruc-
tose administration in normal subjects is about 20 min-
utes.21
In the liver, fructose is phosphorylated by fructoki-
nase to fructose-1-phosphate. Fructose-1-phosphate is
then metabolized to triose phosphates, glyceraldehyde,
and dihydroxyacetone phosphate. A portion of carbon
derived from the triose phosphates can enter the glu-
coneogenic paythway and subsequently be released as
glucose. Thus, a small but measurable increase of circu-
lating glucose can be observed after fructose ingestion or
intravenous infusion of fructose. A significant amount of
fructose carbon entering glycolysis is metabolized to
lactate and released, with smaller amounts released as
pyruvate or alpha-ketoglutarate.21 After ingestion of 45 g
of fructose with a mixed meal, plasma lactate concentra-
tions increased 3-fold (by2 mmol/L), whereas after the
same amount of glucose, plasma lactate only increased
by 0.5 mmol/L.22 Presumably, a portion of this lactate is
later taken up by the liver and enters gluconeogenesis to
be converted to glucose or glycogen, or it can be metab-
olized to form acetyl-CoA.
A key aspect of hepatic fructose metabolism is that
the entry of fructose via fructose-1-phosphate bypasses
the main rate-controlling step in glycolysis, catalyzed by
phosphofructokinase (Figure 1). In contrast, hepatic glu-
cose metabolism is limited by the capacity of the liver to
store glucose as glycogen and, more importantly, by the
inhibition of glycolysis and further glucose uptake re-
sulting from allosteric inhibition of phosphofructokinase
by citrate and ATP (Figure 1). When large amounts of
fructose are consumed, for example, in sucrose- or
HFCS-sweetened beverages, significant quantities of
fructose carbon continue to enter the glycolytic pathway
distal to phosphofructokinase (Figure 1), facilitating
very-low-density lipoprotein (VLDL) and triglyceride
production in the liver. As the glycolytic pathway be-
comes saturated with intermediates, these can be con-
verted to glycerol-3-phosphate, providing the glycerol
moiety of triglyceride synthesis. They can also be further
metabolized to pyruvate, and via pyruvate dehydroge-
nase to acetyl-CoA and citrate in mitochondria to pro-
vide carbon for de novo lipogenesis and to long-chain
fatty acids that are then esterified to form triglycerides.20
Thus, unlike glucose metabolism, in which uptake is
negatively regulated at the level of phosphofructokinase
(Figure 1), high levels of fructose serve as an unregulated
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source of hepatic acetyl-CoA production. While only a
small percentage (1%–3%) of glucose carbon enters de
novo lipogenesis and is incorporated into triglyceride in
normal individuals, a proportionally much greater
amount of carbon from ingested fructose is metabolized
to triglyceride. Indeed, studies in human subjects have
shown that fructose ingestion results in substantially
increased rates of de novo lipogenesis,23 which does not
increase in response to eucaloric glucose ingestion.24
Thus, fructose is more lipogenic than glucose, and this
appears to be a major factor in its effects to induce
hypertriglyceridemia in the postprandial state.
FRUCTOSE AND LIPIDS
As discussed in the previous section, the hepatic metab-
olism of fructose favors lipogenesis, suggesting that
fructose consumption could contribute to increases in
circulating lipid levels. Recent reviews have examined
the role of dietary carbohydrates in general,25 and sugars
in particular,26 in triglyceride metabolism and cardiovas-
cular disease risk. It is well known from studies in
animals, including rodents,27-30 dogs,31 and nonhuman
primates,32 that feeding diets high in energy from fruc-
tose or sucrose induces hyperlipidemia.2 It is the fructose
Figure 1. Fructose and glucose utilization in the liver. Hepatic fructose metabolism begins with phosphorylation by fructokinase.
Fructose carbon enters the glycolytic pathway at the triose phosphate level (dihydroxyacetone phosphate and glyceraldehyde-3-
phosphate). Thus, fructose bypasses the major control point (phosphofructokinase) at which glucose carbon enters the glycolytic
pathway, which limits further glucose metabolism via feedback inhibition by citrate and ATP. These differences in the hepatic
metabolism of fructose compared with glucose allow fructose to serve as an unregulated source of both glycerol-3-phosphate and
acetyl-CoA, leading to enhanced lipogenesis.
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component of sucrose that is considered to increase
triglyceride levels.33
In 1966, Macdonald34 reported that feeding fructose
but not glucose for 5 days increased serum triglycerides
in men and postmenopausal but not premenopausal
women. High-sucrose diets also elevated fasting triglyc-
eride concentrations in humans, while consuming an
equal amount of glucose resulted in lower serum triglyc-
eride levels.28 This effect of sucrose to raise triglycerides
was dose dependent in hyperinsulinemic subjects.35 In
1983, Hallfrisch et al.36 reported that fasting total and
LDL cholesterol were increased after 5 weeks in subjects
consuming diets containing 15% energy from fructose,
and plasma triglyceride concentrations increased in hy-
perinsulinemic subjects as the level of dietary fructose
increased. Swanson et al.37 reported that LDL cholesterol
increased during a 4-week crossover study when normal
subjects consumed a diet containing 20% energy as
fructose, but not when the fructose was replaced with
starch.37 Increases of total and LDL cholesterol during 4
weeks of 20% fructose consumption have also been
reported in subjects with diabetes.38 In another study,
fasting triglyceride and total cholesterol levels increased
in both normal and hyperinsulinemic subjects when they
consumed 20% energy from fructose but not from
cornstarch; VLDL, LDL, and apolipoprotein B100
(ApoB100) were also significantly elevated in the hyper-
insulinemic subjects.39 In contrast, other investigators
have not reported increases of fasting lipids in subjects
with insulin resistance or diabetes when fructose was
consumed at 13%,40 15%,41 or 20%42 of energy.
The inconsistent effects of fructose to induce hyper-
lipidemia may be dependent on the amount of fructose in
the diet, on whether fasting or postprandial lipids are
measured, and on the potential for gender differences in
circulating lipid responses to fructose consumption. Post-
prandial measurements may detect changes in lipid pro-
files that are not detected in the fasting state.43 Certainly
the acute consumption of meals high in fructose or
sucrose (50% fructose) can acutely increase postprandial
triglyceride levels. For example, the addition of 50 g of
fructose or 100 g of sucrose to a 40-g fat meal increased
postprandial triglyceride levels over 7 hours, whereas
consumption of 50 g of glucose with the meal had no
effect on the triglyceride response.44 In a 12-week cross-
over study, Bantle et al.45 compared the effects of 6
weeks of fructose or glucose consumption (17% of en-
ergy) on both fasting and postprandial lipid levels in
normal-weight men and women. Fasting triglyceride
concentrations decreased by approximately 30% over
pre-study levels in men when glucose was consumed, but
were unchanged during the fructose diet. Neither glucose
nor fructose affected fasting triglyceride levels in
women. In addition, day-long plasma triglyceride levels
were elevated by 30% in men consuming fructose com-
pared with glucose; however, postprandial triglycerides
were not different between the glucose and fructose diets
in women.
In a recently published study, the short-term effects
of consuming fructose- and glucose-sweetened bever-
ages (providing 30% of total energy) consumed with
three meals over a 24-hour period were compared in 12
normal-weight young women with normal fasting tri-
glyceride levels.22 In this crossover study, plasma tri-
glyceride concentrations increased more rapidly and
peaked at higher levels after the consumption of fruc-
tose-containing beverages compared with those contain-
ing glucose. Plasma triglyceride concentrations remained
elevated after fructose consumption, but declined below
fasting levels several hours after glucose consumption.
Net triglyceride exposure as assessed by the area under
the curve above fasting levels was not increased when
glucose beverages were consumed, but the area under the
curve was highly positive and total triglyceride exposure
was increased by over 20% above fasting levels on the
day fructose-sweetened beverages were consumed.
In a long-term (10-week) study, the effects of con-
suming diets containing 25% of energy as fructose or
glucose on postprandial triglyceride profiles were exam-
ined in overweight women with normal triglyceride lev-
els.46 A progressive increase in postprandial triglyceride
concentrations (compared with a baseline complex car-
bohydrate diet) was observed over 14 hours in subjects
consuming fructose-sweetened beverages with meals,
and the effect was much more pronounced after 10
weeks than after 2 weeks of fructose consumption. In
contrast, postprandial triglyceride profiles were not in-
creased after 2 or 10 weeks in subjects randomized to
consume glucose-sweetened beverages with meals, de-
spite substantially larger plasma insulin and glucose
excursions when glucose was consumed compared with
the baseline complex carbohydrate diet. In addition,
postprandial ApoB levels increased by approximately
12% after 10 weeks in subjects consuming the high-
fructose diet but not in those subjects on the high-glucose
diet.46 Postprandial triglyceride profiles were also ele-
vated in rhesus monkeys after one year of consuming a
high-fructose diet, but not in animals after one year on a
high-glucose diet (P. Havel, unpublished data), indicat-
ing that the hyperlipidemic effects of consuming fructose
are persistent.
MECHANISMS AND ATHEROGENICITY OF
FRUCTOSE-INDUCED HYPERLIPIDEMIA
Elevated triglyceride levels reflect an imbalance between
the rates of VLDL-triglyceride production and clearance.
A major factor influencing hepatic triglyceride secretion
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is fatty acid availability.47 Hepatic de novo lipogenesis
can increase fatty acid availability by two processes: 1)
by the direct effect of de novo fatty acid synthesis, and 2)
indirectly as the result of increased levels of hepatic
malonyl-CoA, which potently inhibits fatty acid oxida-
tion by blocking fatty acid transport into the mitochon-
dria via carnitine palmitoyltransferase-1.48,49 Both mech-
anisms lead to increased esterification/re-esterification of
fatty acids and increased hepatic triglyceride synthesis
that in turn leads to increased circulating VLDL-triglyc-
eride levels
Acetyl CoA is the principal component of fatty acids
produced by de novo lipogenesis24 and, as previously
discussed, high levels of dietary fructose serve as an
unregulated source of hepatic acetyl-CoA production.
Fractional hepatic de novo lipogenesis is dramatically
increased during fructose ingestion compared with glu-
cose ingestion,23 and it has been reported that nearly
30% of circulating palmitate in triglycerides after fruc-
tose ingestion is from fructose-derived de novo lipogen-
esis.50 In contrast, Hellerstein24 has shown that there is
little de novo lipogenesis from glucose under eucaloric
conditions in humans. There is evidence that the effect of
fructose in increasing postprandial triglyceride levels is
exacerbated in subjects with existing hypertriglyceride-
mia51,52 or insulin resistance.53 Therefore, chronic hy-
perinsulinemia and increased circulating fatty acids,
which are commonly seen with central obesity and insu-
lin resistance, may further increase hepatic de novo
lipogenesis during fructose consumption in subjects with
metabolic syndrome.
Several studies conducted in rodents have investi-
gated the mechanisms by which fructose contributes to
increased triglyceride levels. One study in rats fed 70%
fructose or glucose diets indicated that fructose may
increase de novo lipogenesis by increasing substrate flux
through pyruvate dehydrogenase via inhibition of pyru-
vate dehydrogenase kinase.54 Taghibiglou et al.55 inves-
tigated mechanisms for the overproduction of VLDL in
an insulin-resistant, fructose-fed hamster model (60%
energy from fructose), and found evidence for enhanced
lipoprotein assembly, reduced intracellular ApoB degra-
dation, and increased hepatic expression of microsomal
triglyceride transfer protein. Together, these findings
help explain the increased assembly and secretion of
ApoB-containing lipoproteins in fructose-fed animals.55
It is also possible that reduced triglyceride clearance
could contribute to fructose-induced hypertriglyceride-
mia.
A study in rats suggested that fructose reduced
VLDL-triglyceride removal by lowering the ApoE to
ApoC ratio.56 In addition, the reduced postprandial in-
sulin responses to high-fructose meals22 could lead to
less activation of lipoprotein lipase and decreased tri-
glyceride removal via this mechanism. The reports that
ApoB levels increase during fructose consumption39,46
suggest that increases of VLDL-triglyceride represent a
significant component of fructose-induced increases of
postprandial triglycerides. New studies are needed to
definitively determine the relative contributions of in-
creased production and decreased clearance of VLDL-
triglyceride to the hyperlipidemic effects of fructose
consumption.
In summary, several short-term studies have impli-
cated fructose in promoting unfavorable lipid profiles.
Both short-term and long-term fructose consumption
increase postprandial triglyceride levels. In a preliminary
study, the hypertriglyceridemic effects of fructose were
more pronounced after 10 weeks than 2 weeks, and
fructose consumption also increased postprandial levels
of atherogenic ApoB.46 High triglyceride levels are an
independent risk factor for coronary heart disease.57,58
This understanding is based largely on evidence meta-
analyses of population-based studies.59-61 Moderate in-
creases of VLDL-triglyceride are associated with other
lipoprotein changes, including reduced HDL62,63 and
small, dense LDL,64,65 which are components of the
metabolic syndrome and are recognized as risk factors
for atherosclerotic disease.
Our unpublished data demonstrate a strong correla-
tion between the observed increases in postprandial tri-
glycerides and ApoB after 10 weeks of high fructose
consumption. Atherogenic risk is strongly dependent
upon plasma lipoproteins containing ApoB100,66 which
facilitates the accumulation of cholesterol and other
lipids into the arterial wall by multiple mechanisms.67,68
Although consumption of fructose can increase triglyc-
erides and ApoB, the effects of fructose consumption on
other potential markers and mediators of atherogenesis
and/or inflammation, such as small, dense LDL, remnant
lipoproteins, interleukin-6, C-reactive protein, and plate-
let activator inhibitor-1, have not been investigated.
FRUCTOSE AND INSULIN RESISTANCE
Insulin resistance, along with visceral obesity, dyslipide-
mia, and hypertension, is a major component of the
metabolic syndrome and is strongly associated with an
increased risk for cardiovascular disease. When com-
bined with impaired islet/-cell function in genetically
predisposed individuals, insulin resistance leads to type 2
diabetes. Feeding diets containing high levels of fructose
impairs insulin action in animals. Feeding fructose or
sucrose (50% fructose) to animals has often been em-
ployed to produce animal models of insulin resistance.
Consumption of a high fructose diet for 4 weeks in rats
induced systemic insulin resistance and reduced tyrosine
phosphorylation of the insulin receptor in liver, as well as
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impaired insulin-stimulated IRS-1 phosphorylation and
IRS-1 association with phosphoinositol-3-kinase in both
liver and skeletal muscle,69 suggesting specific points in
the insulin signal transduction pathway that are affected
by dietary fructose. The effects of dietary sugars on
insulin action in animals and humans have been exam-
ined in several recent reviews.2,70-72 When compared
with studies conducted in experimental animals, much
more limited data are available concerning the effects of
fructose consumption on insulin action in humans.
Accurate assessment of insulin sensitivity requires
specific methods such as hyperinsulinemic clamps or
fast-sampled intravenous glucose tolerance tests with
mathematical modeling of insulin action. Without such
methods, insulin sensitivity must be estimated by mea-
suring fasting insulin levels or employing indices such as
the homeostasis assessment model, which are derived
from measurements of fasting insulin and glucose. How-
ever, while fasting insulin and derivations thereof are
more suitable for larger epidemiological studies, gener-
ally these measurements lack the sensitivity required to
assess insulin action in smaller-scale interventional ex-
periments.
In 1980, Beck-Nielsen et al.73 reported that over-
feeding human subjects fructose at 1000 kcal/d was
accompanied by reductions in insulin binding to mono-
cytes in vitro and in whole-body insulin sensitivity as
determined by an intravenous insulin tolerance test,
whereas glucose overfeeding (also 1000 kcal/d) had no
effects on insulin binding or insulin sensitivity. Hall-
frisch et al.74 reported that consumption of diets contain-
ing 15% of energy as fructose resulted in undesirable
changes in glucose metabolism, as suggested by in-
creased glucose and insulin responses to an oral sucrose
load; these effects were more pronounced in hyperinsu-
linemic subjects. In contrast, results from several other
studies did not demonstrate any measurable effects of
fructose consumption on insulin action.42,75,76 Similar
discrepancies have been reported in studies in which
fructose was provided as 50% of dietary sucrose.77-79
Potential explanations for the discrepancies between hu-
man studies include the amount (dose) of the sugars
included in the diet, the duration of dietary intervention,
and the other components included in the background
diet around which sugar content was manipulated. For
example, if the intervention diet is low in fat, this might
lessen the effects of the fructose component to impair
insulin action. In addition, some studies compared the
effects of dietary fructose with sucrose such that the
comparison diet already contained half the amount of the
fructose available in the intervention diet. Another im-
portant consideration is that normal-weight and/or insu-
lin-sensitive subjects might be relatively resistant to the
insulin-desensitizing effects of sustained fructose con-
sumption, whereas fructose may be more likely to exac-
erbate insulin resistance in subjects with existing deficits
in insulin action. Such differential sensitivity to the
adverse effects of dietary fructose may be similar to the
better-documented effects of fructose to further increase
triglycerides in subjects with existing hypertriglyceride-
mia (as discussed above).
Although fructose does not directly stimulate insulin
secretion, insulin secretion will increase, resulting in
compensatory hyperinsulinemia, if long-term fructose
consumption leads to obesity and insulin resistance. In
addition, insulin resistance often coexists with increased
levels of circulating fatty acids80 and triglycerides,81
which have been implicated in the etiology of insulin
resistance.
Perhaps the most compelling link between lipid
metabolism and insulin resistance is that both circulating
free fatty acids and fatty acids derived from triglycerides,
as well as those synthesized locally, can lead to ectopic
fat deposition in liver and skeletal muscle. Liver triglyc-
eride content and intramyocellular lipid content are
closely linked to liver and muscle insulin resistance,
respectively.82-84 Thus, the lipogenic effects of fructose
already discussed may contribute indirectly to insulin
resistance via accumulation of fructose-derived lipids in
liver and skeletal muscle during long-term overconsump-
tion of fructose. High-fructose diets can increase hepatic
triglyceride content in humans,85 and the decreased ex-
port of triglycerides synthesized in the liver may contrib-
ute to this effect.86 Fructose feeding in rats not only
increases circulating triglyceride and free fatty acid con-
centrations,40 but also leads to lipid deposition in liver
and muscle,87,88 which may contribute to the observed
induction of insulin resistance. In addition, administra-
tion of the peroxisome proliferator-activated receptor-
alpha (PPAR) agonist fenofibrate improves fructose-
induced insulin resistance, in association with reductions
of circulating triglyceride and free fatty acid concentra-
tions and tissue triglyceride levels.87,88 If ectopic fat
deposition does indeed contribute to the development of
fructose-induced insulin resistance, many of the previous
studies investigating the effects of fructose on insulin
action may have been too short in duration for liver and
muscle triglycerides to accumulate to the extent that
insulin action would be measurably compromised.
Reduction of hypertriglyceridemia induced with
several pharmacological agents reverses the insulin re-
sistance induced by fructose feeding in rats.27,88,89 As
previously discussed, postprandial hypertriglyceridemia
after fructose ingestion is exacerbated in humans53 and
rhesus monkeys with high fasting insulin levels (unpub-
lished observation), also suggesting an interaction be-
tween insulin resistance and the lipogenic effects of
fructose. Hepatic gluconeogenic and lipogenic pathways
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share common precursors and can be coordinately regu-
lated. Prior studies have indicated that the normal liver
can accommodate increased gluconeogenic precursor
flux. However, when a large quantity of fructose, which
is metabolized to gluconeogenic precursors such as lac-
tate and pyruvate, is infused, both glucose production90
and de novo lipogenesis50 are increased. There is evi-
dence for increased hepatic flux of gluconeogenic pre-
cursors in insulin-resistant subjects, and this has been
suggested as a common mechanism underlying both
hyperglycemia and hypertriglyceridemia.91-93 In clamp
studies utilizing tracer methodology, Dirlewanger et al.94
demonstrated that intravenous fructose infusion acutely
induced insulin resistance as determined by glucose
clamp studies and increased hepatic glucose output. An
impairment of glucose disappearance was also reported
in this study, but the mechanism was not identified.
In summary, while it is clear that fructose feeding
can induce insulin resistance and glucose intolerance in
experimental animals (mainly rodents), few long-term
studies have been conducted in humans. The potential
mechanisms involved in fructose-induced insulin resis-
tance include direct effect on insulin signaling, direct
effects on hepatic glucose production, and indirect ef-
fects resulting from hepatic and muscle lipid accumula-
tion. It is possible that these mechanisms have additive or
synergistic effects in the induction of insulin resistance.
Because it is evident that fructose consumption has
increased significantly, new studies are needed to sys-
tematically investigate the long-term effects of fructose
on insulin action and glucose tolerance, particularly in
hypertriglyceridemic individuals with hyperinsulinemia
who are at increased risk for cardiovascular disease. It is
important in such studies to employ appropriate methods
to assess insulin sensitivity and to determine the effects
of fructose on hepatic glucose metabolism, as well as
hepatic and intramyocellular lipid accumulation.
FRUCTOSE AND DIABETES
Smith et al.21 were among the first to investigate the
metabolism of fructose in subjects with diabetes mellitus,
reporting that the half-life of fructose was prolonged and
that urinary glucose excretion after fructose infusion was
greater in diabetic than in normal subjects, suggesting
that the conversion of fructose to glucose is increased in
diabetes. This may be the result of higher rates of
gluconeogenesis from lactate and pyruvate generated
from fructose in subjects with diabetes. The role of
dietary carbohydrates, and sugars in particular, in the
nutritional management of diabetes mellitus has recently
been reviewed in detail.95 In the past, fructose has been
recommended as a dietary sweetener in the nutritional
management of diabetes because it reduces postprandial
hyperglycemia compared with sucrose. Fructose inges-
tion also results in smaller postprandial glucose excur-
sions compared with the ingestion of glucose and glu-
cose-containing carbohydrates (starches), which are
rapidly absorbed as glucose.22,96
Infusion of small amounts of fructose into the portal
vein increases hepatic uptake of glucose,97 an effect that
may be mediated by induction of hepatic glucokinase.
Small quantities of fructose also increase carbon flux
through glycogen synthase, stimulate glycogen synthe-
sis,98 and restore the ability of hyperglycemia to regulate
hepatic glucose production in humans.99 Thus, small
quantities of fructose appear to have a “catalytic” effect
to improve hepatic glucose uptake and storage as glyco-
gen, perhaps as a consequence of activation of hepatic
glucokinase.98,100 The addition of 7.5 g of fructose to a
75-g oral glucose tolerance test reduced the glycemic
response in adults with type 2 diabetes,101 suggesting
that limited amounts of oral fructose would be useful in
improving glycemic control in type 2 diabetes.
Several studies have demonstrated that the addition
of small to moderate amounts of fructose or sucrose to
the diet has no deleterious effects, and even some bene-
ficial effects, on glucose metabolism in subjects with
type 2 diabetes.41,102-106 For example, Osei et al.107 fed
60 g/d of fructose (10%–15% of energy) with isoca-
loric weight-maintaining diets to 13 patients with poorly
controlled type 2 diabetes for 6 months in a crossover
study with the control diet providing mainly complex
carbohydrate. Fasting glucose decreased from 227 to 176
mg/dL and glycosylated hemoglobin decreased from
11.3% to 9.9%.107 Using more sophisticated approaches
for assessing glucose metabolism (hyperinsulinemic eu-
glycemic clamps), Thorburn et al.108 reported that after 3
months on a diet providing 13% of energy as fructose to
subjects with type 2 diabetes, hepatic glucose produc-
tion, hepatic insulin sensitivity (insulin-mediated sup-
pression of endogenous glucose production), and periph-
eral glucose disposal were all unchanged. Unfortunately,
because the baseline comparison diet in this study con-
tained 13% sucrose, the incremental difference of fruc-
tose intake on the higher-fructose diet was only 6.5% of
energy consumed. Nonetheless, most studies conducted
to date have not demonstrated adverse effects on con-
suming moderate amounts of fructose on glycemic con-
trol or insulin sensitivity in patients with type 2 diabetes
during periods of neutral energy balance.
Of greater concern, however, is the potential impact
of consuming large amounts of fructose on lipid metab-
olism in subjects with type 2 diabetes, who are at a
substantially increased risk of cardiovascular disease. A
number of studies examining the effects of dietary fruc-
tose in patients with type 2 diabetes have not reported
increases of fasting lipids.41,103 Osei et al.107 found no
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increase of fasting cholesterol, triglycerides, or ApoA1
or ApoB100 in type 2 diabetic subjects after six months
on a diet providing 60 g of fructose per day. Thorburn et
al.40 also reported no deleterious changes of lipid metab-
olism, including free fatty acids, total cholesterol, LDL,
or VLDL production rates assessed by labeled glycerol
incorporation into triglyceride, when comparing 13%
fructose with 13% sucrose diets. However, in another
study by the same investigators, a 20% fructose diet did
increase triglyceride levels after 2 weeks in diabetic
subjects with higher baseline fasting hypertriglyceride
levels (150 mg/dL).51 In another study employing a
20% fructose diet in diabetic subjects, total and LDL
cholesterol were increased by 7% and 11%, respectively,
after 4 weeks.38 Thus, the existing data regarding the
effects of moderate amounts of dietary fructose on lipids
in subjects with type 2 diabetes are equivocal. Given the
more extensive and more recent data demonstrating ad-
verse effects of fructose consumption on lipids, particu-
larly postprandial triglyceride and ApoB levels, new
studies are needed to investigate the effects of fructose
consumption in this at-risk population. Of particular
interest is the impact of dietary fructose when it is
consumed in combination with high-fat meals in a setting
of positive energy balance rather than in the setting of
neutral energy balance (eucaloric feeding) employed in
most clinical nutrition studies.
There are other potential concerns regarding fruc-
tose consumption in patients with type 2 diabetes. Com-
pared with glucose, fructose ingestion only weakly stim-
ulates insulin secretion. In addition to insulin’s
involvement in the long-term regulation of energy bal-
ance, augmentation of insulin secretion is an important
goal of diabetes therapy, particularly since the early
insulin response to meals is an important determinant of
postprandial glucose control.109-111 In addition, the lack
of effects of dietary fructose on the endocrine signals
involved in the long-term regulation of energy balance
discussed in the following section suggests that pro-
longed consumption of a high-fructose diet, along with
dietary fat and inactivity, could contribute to weight gain
and therefore worsen insulin resistance and other risk
factors for cardiovascular disease.
Finally, little is known regarding the effects of
fructose on diabetic complications, specifically the po-
tential impact of fructose to contribute to protein fructo-
sylation112 and oxidative stress.113 Significant amounts
of fructose may escape hepatic uptake, resulting in in-
creased systemic circulating fructose concentrations after
consumption of large quantities of fructose (e.g., sweet-
ened beverages). Fructose is a major product of the
polyol/sorbitol pathway, and tissue fructose accumula-
tion has been implicated in diabetic neuropathy and other
complications of diabetes.114-116 These complications
could reflect increases of protein fructosylation. In a
recent study, a diet providing 40% of energy from
fructose increased both the formation of cataracts and
oxidative by-products in the kidneys of streptozotocin
diabetic rats compared with a high-glucose control
diet.117 Increased glycation (fructosamine and glycated
hemoglobin) and markers of lipid peroxidation and aging
have been observed in rats consuming a high-fructose
diet compared with animals consuming a high-glucose
diet.118 Fructose feeding decreases antioxidant defense
systems,119,120 and oxidative stress has been implicated
as a contributing factor in insulin resistance and impaired
beta-cell function.121,122 In contrast, one long-term study
in non-diabetic rats consuming fructose, glucose, su-
crose, or starch as the sole source of dietary carbohydrate
found no differences in levels of advanced glycation
end-products in collagen.123 It is not known whether
glycation and oxidation-related products are increased
and could contribute to diabetic complications in humans
with type 2 diabetes who consume high levels of dietary
fructose.
In summary, existing data from short-term studies
indicate that small to moderate amounts of dietary fruc-
tose do not adversely impact, and may even improve,
glycemic control in patients with type 2 diabetes. Some,
but not all, studies suggest the potential for undesirable
effects of fructose consumption on lipid metabolism in
type 2 diabetes. Patients with existing hyperlipidemia
may be at increased risk for fructose-induced dyslipide-
mia. The potential for sustained consumption of a diet
high in fructose to contribute to weight gain and diabetic
complications is also a concern. New studies are needed
to investigate the long-term metabolic impact of fructose
in diabetes.
FRUCTOSE, ENERGY HOMEOSTASIS, AND
OBESITY
Short-term versus Long-term Regulation of
Energy Homeostasis
Body weight and adiposity are tightly regulated over
relatively long periods of time. Even after large alter-
ations of body fat resulting from restriction of energy
intake or overfeeding, body weight and fat stores tend to
return to pre-intervention levels when ad libitum feeding
resumes.124,125 Food intake, energy expenditure, and
body fat stores are regulated by a variety of nutrient,
endocrine, and neural signals originating in the periphery
and providing information to the central nervous system
centers in the hindbrain and hypothalamus that coordi-
nate energy homeostasis.3 Food intake and energy bal-
ance are regulated by distinct, but interacting, short-term
and long-term mechanisms. Incoming nutrients, disten-
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sion of the stomach and upper intestine, as well as a
number of hormones produced by the gut, including
cholecystokinin (CCK) and glucagon-like peptide-1
(GLP-1), act as short-term signals of satiety that limit
meal duration and meal size. However, these short-term
signals are not, by themselves, able to regulate body
adiposity in the long term.
Other long-term endocrine regulators of energy ho-
meostasis are released in proportion not only to body fat
stores, but also to the quantity and macronutrient com-
position of food consumed over more prolonged periods.
Insulin secreted by the endocrine pancreas, leptin pro-
duced by adipocytes, ghrelin from the stomach, and
possibly peptide YY3-36 (PYY3-36) from the distal intes-
tine appear to be involved in the long-term regulation of
energy balance and body adiposity (Figure 2). Changes
in the production and circulating levels of these hor-
mones help to ensure that appetite, food intake, and
metabolic rate are appropriately modified in order to
maintain body weight/fat stores in energy balance. Ad-
justments in the production of long-term hormonal sig-
nals appear to function as determinants of the effective-
ness of the short-term signals to decrease meal size and
duration. For example, following a period of energy
restriction during which insulin secretion and leptin pro-
duction are diminished and circulating ghrelin levels are
increased, a larger extent of gastrointestinal distension
and greater CCK and GLP-1 release are required to
signal satiety to the CNS and induce cessation of eat-
ing.126-128 In the next sections, the major long-term
endocrine signals known to be involved in the regulation
of energy homeostasis are reviewed and recent data
examining the effects of fructose consumption on these
hormones are discussed.
Insulin
Insulin is involved in the regulation of body adiposity via
its actions in the CNS to inhibit food intake and increase
energy expenditure.129,130 Insulin is secreted in response
to the ingestion of glucose-containing carbohydrates and
certain amino acids released from ingested protein, as
well as cephalic phase activation of vagal neural input to
the pancreas131 and the gastrointestinal incretin hor-
mones GIP and GLP-1.132 Insulin receptors are highly
expressed in several CNS areas involved in the control of
food intake and energy homeostasis, including the hypo-
thalamus. Direct administration of insulin into the CNS
inhibits food intake in animals, including nonhuman
primates. Genetic or antisense inactivation of insulin
receptor function or administration of inhibitors of insu-
lin signal transduction in the CNS results in increases of
food intake and body adiposity in rodents.133-135 Insulin
appears to inhibit food intake by activating phosphati-
dylinositol 3-kinase (PI-3-kinase) in specific hypotha-
lamic nuclei, a signaling pathway that is shared with
leptin in its effects to reduce food intake.136 Accordingly,
reduced insulin delivery or disruption of CNS insulin
signaling result in weight gain and obesity.
Insulin does, however, have well-described periph-
eral anabolic effects to stimulate lipid synthesis and
storage. These actions of insulin, along with the idea that
reactive hypoglycemia resulting from insulin responses
to dietary carbohydrate is commonplace, has led to a
widespread misconception that insulin causes weight
gain and obesity, and to the promotion of numerous diets
suggesting that weight loss can be achieved simply by
avoiding foods that stimulate insulin secretion (i.e., the
recent low-carbohydrate and low-glycemic-index diet
fads). However, the proponents of low-carbohydrate di-
ets do not differentiate between insulin responses to
meals, when circulating insulin concentrations rapidly
increase and then return to baseline levels, and chronic
hyperinsulinemia secondary to -cell adaptation to insu-
lin resistance.
Although chronic hyperinsulinemia does appear to
increase hepatic lipogenesis and may contribute to hy-
pertriglyceridemia, as previously discussed, a direct con-
nection between hyperinsulinemia and weight gain has
not been established. It is possible that in the presence of
central insulin (and leptin) resistance, the peripheral
anabolic effects of insulin are unopposed and could
contribute to lipogensis and weight gain. For example,
this may be the case in syndromes of hypothalamic
obesity, in which impaired central insulin and leptin
action, combined with autonomic dysfunction driving
excess insulin secretion, may contribute to the pathogen-
esis of obesity. Examples of this include certain animal
models such as ventromedial hypothalamus or gold thio-
glucose-lesioned rodents137 and humans with hypotha-
lamic damage.138 With regard to the glycemic index of
dietary carbohydrate, Anderson et al.139 reported that the
ingestion of carbohydrates that induced larger glucose
excursion and would be expected to more potently stim-
ulate insulin secretion actually resulted in lower short-
term appetite ratings and a decrease of ad libitum food
intake one hour later.
Peripheral effects of hyperinsulinemia notwithstand-
ing, little evidence directly implicates insulin responses
to meals as a causal factor in weight gain and obesity. In
fact, reduced insulin responses to oral and intravenous
glucose and to meal ingestion have been shown to be
predictive of greater future weight gain in Pima Indi-
ans140 and of subsequent increases of visceral fat mass in
Japanese Americans.141 These data suggest that, under
most conditions, insulin responses to meals are in fact
protective against, rather than contributors to, weight
gain and obesity. In addition, the insulin response to
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meal ingestion is an important mediator of leptin pro-
duction by adipose tissue (see below).
Previous studies have shown that fructose, unlike
glucose, has at most weak effects to stimulate insulin
secretion from pancreatic -cells in vitro142,143 or in
vivo.102,144 The most likely explanation for the lack of
effects of fructose on insulin secretion is the low level of
expression of the GLUT5 fructose transporter in
-cells.145 Most of the small effects of ingested fructose
to increase insulin is likely to result from the hepatic
conversion of fructose to glucose discussed in the section
on fructose metabolism and the release of the incretin
hormones GIP and GLP-1.22,146,147 A recently published
study demonstrated that the integrated insulin responses
to three mixed macronutrient meals consumed with fruc-
tose-sweetened beverages were reduced by about 60%
compared with when the same meals were consumed
with equicaloric glucose-sweetened beverages.22 A sim-
ilar persistent reduction of meal-induced insulin secre-
tion has been observed in subjects consuming fructose-
sweetened beverages with meals for 10 weeks
(unpublished observation). Therefore, based on insulin’s
role as a component of the endocrine systems involved in
long-term regulation of body weight, decreased meal-
induced insulin secretion could contribute to increased
energy intake and weight gain during sustained con-
sumption of a high-fructose diet.
Glucose, independent of insulin, appears to have a
direct role in regulating food intake that may not be
shared by fructose. Glucose transport through brain cap-
illaries for utilization by the CNS is mediated by GLUT3
and does not require insulin, whereas fructose does not
readily cross the blood-brain barrier,148 most likely due
to the lack of GLUT5-mediated transport.149 Since sig-
naling in glucose-sensitive/-responsive neurons via glu-
cose metabolism has been implicated in the regulation of
food intake,150-152 the lack of transport of fructose across
the blood-brain barrier and access to these neurons could
potentially contribute to dysregulation of food intake and
energy balance when high levels of dietary fructose are
consumed.
Leptin
Leptin, which is produced by adipocytes, serves as a
critical endocrine signal to the CNS in the regulation of
food intake, energy expenditure, and body adiposity.153
The actions of insulin and leptin to reduce food intake
share a common signaling pathway via activation of
PI-3-kinase.154 Defects in the ability to produce leptin155
or the leptin receptor156 lead to marked hyperphagia and
morbid obesity in humans. Administration of recombi-
nant leptin reduces the appetite and produces marked
weight loss in leptin-deficient patients.157 A relative
deficiency in the ability to produce leptin resulting from
heterozygous mutations in the leptin gene is associated
with increased body fat.158 Circulating leptin concentra-
tions are decreased during dieting, and the decreases
are related to increased sensation of hunger in dieting
women.159
Administration of low doses of exogenous leptin has
been shown to reduce appetite in patients with low leptin
levels resulting from lipodystrophy160 and in obese sub-
jects during an energy-restricted diet.161 Leptin replace-
ment also prevents the decreases of energy expenditure
and thyroid axis function normally observed in humans
during an energy-restricted diet.162 Based on these ob-
served effects, decreased leptin production during dieting
and weight loss would be expected to contribute to
hunger, lowered metabolic rate, and subsequent weight
regain. Also of interest are clinical studies showing that
low-dose leptin administration improves insulin resis-
tance and hyperlipidemia in association with marked
reductions of liver and muscle lipid deposition in sub-
jects with low leptin levels due to lipodystrophy.163
These effects are associated with reduced triglyceride
deposition in liver and skeletal muscle.164,165 It is now
abundantly clear that leptin has a crucial role in the
regulation of energy and metabolic homeostasis in hu-
mans.166
Although circulating leptin concentrations are
highly correlated with body adiposity,167,168 leptin levels
fall during short-term fasting169 or caloric restriction170
to a much greater degree than would be expected from
the small changes of body fat mass. Plasma leptin levels
do not increase until more than 4 hours after the inges-
tion of a meal, indicating that leptin is not a signal
directly involved in the short-term regulation of satiety,
but rather that changes of leptin in response to nutritional
status act in the medium- to long-term regulation of
energy balance.3,166 Circulating leptin concentrations ex-
hibit a diurnal pattern,171 with a mid-morning nadir and
a nocturnal peak occurring between midnight and 2:00
AM. This diurnal variation is not observed in fasted
subjects,172 but is entrained by meal timing173 and is
proportional to insulin responses to meals. Insulin in-
creases leptin gene expression and leptin secretion, and is
the dominant physiological signal in the regulation of
leptin production and its diurnal pattern.153 Infusion of
insulin at rates producing physiological increases of
plasma insulin levels stimulates circulating leptin with a
time lag of approximately 4 hours, similar to the delay in
leptin production after meal ingestion.174 The effects of
insulin to increase glucose transport and oxidative glu-
cose metabolism appear to be critical for the actions of
insulin to increase leptin production by adipocytes175-177
and for the increase of circulating leptin in response to
insulin and glucose administration in humans.178
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When human subjects consumed high-fat meals re-
sulting in smaller postprandial glucose and insulin ex-
cursions, plasma leptin concentrations over a 24-hour
period were substantially reduced and the amplitude of
the diurnal leptin peak was blunted compared with low-
fat/high-carbohydrate meals.179 Decreased leptin pro-
duction could contribute to the effects of high-fat diets to
induce weight gain and obesity.180-182 The ability of a
low-fat/high-carbohydrate diet to maintain the amplitude
of the diurnal leptin pattern was highly predictive of the
loss of body weight and decreased adiposity observed in
humans subjects on an ad libitum diet.183 These data
suggest that regulation of leptin production by dietary
macronutrient composition has a long-term biological
impact on energy homeostasis in humans.
Plasma leptin concentrations increased progres-
sively with a time delay of about 3 to 4 hours, along with
markedly elevated plasma glucose and insulin concen-
trations, during intravenous infusion of glucose in rhesus
monkeys. In contrast, insulin secretion and leptin con-
centrations were not increased during infusion of the
same amount of fructose.144 In a recently published study
examining the effects of fructose ingestion in humans, 12
women consumed three meals accompanied by fructose-
containing beverages on one day and glucose-containing
beverages on a separate day. Consumption of fructose-
sweetened beverages with meals resulted in smaller
postprandial glucose and insulin excursions than the
consumption of beverages sweetened with glucose. Cir-
culating leptin concentrations over 24 hours were re-
duced by approximately 35%, and the amplitude of the
diurnal leptin pattern was blunted on the fructose day
compared with the glucose day.22 In a longer-term study,
this effect persisted during 10 weeks of fructose con-
sumption.184 Therefore, reductions of leptin production
and the amplitude of the diurnal leptin profile could lead
to increased energy intake, weight gain, and obesity in
individuals habitually consuming diets containing a sub-
stantial amount of energy derived from fructose.
Ghrelin
Ghrelin is a peptide hormone primarily produced by the
stomach and upper small intestine that was first identified
based on its effects to stimulate growth hormone secre-
tion.185 Ghrelin also appears to be involved in the regu-
lation of food intake, substrate metabolism, and body
composition.3,186 The administration of exogenous ghre-
lin increases food intake and, with repeated administra-
tion, reduces lipid oxidation and induces weight gain in
rodents.187,188 Hunger and ad libitum food intake are
increased during intravenous ghrelin infusion in normal
human subjects189 and in patients with cancer-induced
anorexia.190 However, fasting ghrelin levels do not pre-
dict ad libitum energy intake.191
Circulating ghrelin levels are inversely related to
body weight187,192 and increase after diet-induced weight
loss,193,194 suggesting that increases of ghrelin after
weight loss could contribute to hunger and weight regain.
The increases of ghrelin after weight loss resulting from
diet and exercise are not observed in patients who have
lost weight after gastric by-pass surgery,193,195 which
may contribute to the high rate of success of this proce-
dure to produce sustained weight loss. In contrast, circu-
lating ghrelin concentrations are markedly elevated in
Prader-Willi syndrome, a genetic disorder characterized
by marked hyperphagia and obesity.196,197 Plasma ghre-
lin concentrations decrease shortly after ingestion of a
meal and remain suppressed for 2 to 3 hours thereafter.
Postprandial suppression of ghrelin is blunted in obese
subjects.198 There is evidence that insulin and glucose
responses to meals contribute to the suppression of
ghrelin after meals.199-201 Recent published studies dem-
onstrated an approximately 35% decrease of plasma
ghrelin levels after each of three meals accompanied by
a glucose-sweetened beverage; however, postprandial
suppression of ghrelin was substantially diminished
when fructose-sweetened beverages were consumed with
the same meals.22 These results suggest that by failing to
suppress ghrelin secretion, fructose consumption could
lead to increased energy intake and weight gain.
PYY3-36
PYY3-36 is a peptide hormone related to pancreatic
polypeptide and neuropeptide-Y that is produced by the
colon and released into the circulation in response to
nutrient ingestion.202-204 PYY administration inhibits
food intake in rodents,205,206 although this has not been
reported by all investigators.207 Because PYY does not
decrease food intake in Y2 receptor knock-out mice,
inhibition of food intake by PYY appears to involve
binding to presynaptic Y2 receptors that inhibit neu-
ropeptide-Y release from neurons in the arcuate nucleus
of the hypothalamus. Administration of PYY3-36 reduces
appetite/hunger ratings and decreases food intake in
normal-weight and obese subjects.205,208 A relatively
short-term (90-minute) infusion of PYY3-36 produces a
more prolonged reduction of appetite and food intake in
humans.205 Thus, in contrast to most gastrointestinal
peptides that only inhibit short-term food intake,
PYY3-36 may function as a medium- to long-term regu-
lator of energy intake rather than as a short-term satiety
signal. The effect of fructose ingestion on the secretion
and circulating levels of PYY3-36 has not yet been reported.
FRUCTOSE, WEIGHT GAIN, AND OBESITY
Although energy intake, body weight, and adiposity all
increase in animals consuming high-fructose diets,2 con-
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siderably less information is available from studies in
humans. Epidemiological studies have implicated the
intake of beverages that are high in energy from fructose
with increased risk of weight gain and obesity. In data
recently reported from the Nurses’ Health Study, con-
sumption of larger amounts of sugar-sweetened bever-
ages was associated with greater weight gain and an
increased risk of developing type 2 diabetes over a
9-year period in young and middle-aged women209 Chil-
dren who consume more than 265 mL (9 oz.) of carbon-
Figure 2. Long-term signals regulating food intake and energy homeostasis. Insulin and leptin are important long-term regulators of
food intake and energy balance. Both insulin and leptin act in the CNS to inhibit food intake and to increase energy expenditure, most
likely by activating the sympathetic nervous system (SNS). Insulin is secreted from the -cells in the endocrine pancreas in response
to circulating nutrients (glucose and amino acids) and to the incretin hormones glucose-dependent insulinotropic polypeptide (GIP)
and glucagon-like peptide-1 (GLP-1), which are released during meal ingestion and absorption. Insulin can also act indirectly by
stimulating leptin production from adipose tissue via increased glucose metabolism. In contrast, dietary fat and fructose do not
stimulate insulin secretion and therefore do not increase leptin production. Ghrelin, a hormone produced by endocrine cells in the
stomach, increases food intake and decreases fat oxidation and appears to have an anabolic role in long-term regulation of energy
balance. Ghrelin secretion is normally suppressed after meals, but is not suppressed by fructose consumption. The long-term signals
interact with the short-term signals in the regulation of energy homeostasis and appear to set sensitivity to the satiety-producing
effects of short-term signals such as gastrointestinal stretch- and chemo-receptors and peptides such as cholecystokinin (CCK).
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ated soft drinks per day had increased energy intake
compared with those children who do not regularly
consume soft drinks210 In a longitudinal study of more
than 500 schoolchildren, for each serving of sugar-
sweetened beverages consumed, body mass index in-
creased by 0.25 kg/m2 and the likelihood of obesity was
significantly increased.211 A recent study conducted in
the United Kingdom compared a randomized control
group of 319 children aged 7 to 11 years with an
intervention group of 325 children participating in a
nutrition education program aimed at reducing the con-
sumption of carbonated soft drinks. The authors reported
that after 12 months, the percentage of overweight and
obese children in the control group increased by 7.5%,
while the proportion of overweight and obese children in
the control group was unchanged.212 A high level of
consumption of sweetened beverages is particularly
prevalent among Native-American children and teenag-
ers, a population at increased risk for obesity and type 2
diabetes.213 A 3-year intervention study that included a
component aimed at reducing sweetened beverage intake
lowered fasting insulin levels in Native-American high
school students, suggesting a decreased risk for devel-
opment of type 2 diabetes.214
In studies in which subjects were provided with
supplemental fructose or sucrose as beverages, the sub-
jects did not compensate for the additional energy con-
sumed as sugars by reducing their energy intake from
other sources.215-217 One explanation for these observa-
tions could be the lack of effect of fructose ingestion on
the production of hormones that have key roles in the
long-term regulation of food intake and energy expendi-
ture. As previously discussed, results of a recently pub-
lished study demonstrated that ingestion of fructose-
sweetened beverages with a mixed meal resulted in
substantially smaller postprandial plasma glucose and
insulin excursions and attenuated circulating leptin pro-
files compared with when glucose beverages were con-
sumed with the same meal.22
The smaller postprandial excursions of circulating
glucose and insulin after consumption of fructose bever-
ages with meals may have also contributed to the ob-
served attenuated suppression of ghrelin secretion after
high-fructose meals. The decreases of insulin secretion
and leptin production, along with the relative elevation of
plasma ghrelin concentrations observed with fructose
consumption, suggest an endocrine mechanism by which
long-term fructose consumption could contribute to de-
creased satiety and increased food intake (Figure 2). It
was also reported that consumption of fructose beverages
was associated initially with increased hunger and sub-
sequently with an increased intake of fat during ad
libitum feeding the day after fructose exposure.22 How-
ever, this effect was only observed in the subset of
subjects exhibiting a psychological profile of dietary
restraint that reflects a specific behavioral deportment
towards food and dieting. Based on these preliminary
data, further investigation of the potential interactions
between behavioral traits, dietary macronutrient compo-
sition, and physiological determinants of food intake
(e.g., insulin, leptin, and ghrelin) is warranted.
As discussed in detail earlier, fructose consumption,
along with the intake of added sugars and total energy
intake, has increased significantly over the past two to
three decades. The main sources of dietary fructose are
HFCS and sucrose. The lower cost of HFCS may have
contributed to an increase in its use by permitting an
increase in portion size of sweetened beverages without
a proportionate increase in price, resulting in an increase
in the total amount of fructose and the total number of
calories consumed. A major issue with dietary fructose is
that the endocrine profile elicited—decreased insulin
secretion, a reduced diurnal leptin amplitude, and atten-
uated suppression of ghrelin22—appears more similar to
that of dietary fat than that of glucose-containing carbo-
hydrates.179 This endocrine profile, when extrapolated to
the larger population, may have facilitated an increase of
total caloric intake and thereby contributed to popula-
tion-based weight gain. Thus, increased fructose con-
sumption, along with decreased physical activity and
consumption of large portions of high-fat foods, may be
an important contributing factor to the recent obesity
epidemic. The incidence and prevalence of obesity in
adults and children has increased over the same time
period as the increase in fructose consumption. 218-220
SUMMARY
Fructose consumption, along with that of added sugars
and total energy intake, has increased over the last three
decades. These increases coincide with increases in the
prevalence of obesity across the age spectrum. Fructose
metabolism in the liver favors lipogenesis. A number of
studies have shown that fructose consumption induces
hyperlipidemia, particularly increases of triglycerides
during the postprandial period. These effects may be
exacerbated in people with the metabolic syndrome, i.e.,
existing hyperlipidemia and insulin resistance. The im-
pact of fructose on insulin action is less well docu-
mented, but deserves further study. Including small to
moderate amounts of fructose in the diet of patients with
diabetes does not appear to be detrimental and may have
favorable effects on hepatic glucose metabolism. The
effects of consuming large amounts of fructose on dia-
betes, including the potential for worsening of hyperlip-
idemia and insulin resistance or contributing to weight
gain and diabetic complications, is not known. The lack
of effects of fructose on the known endocrine regulators
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of long-term energy balance, insulin, leptin, and ghrelin,
suggest that prolonged consumption of a diet high in
energy from fructose would contribute, along with di-
etary fat and inactivity, to positive energy balance,
weight gain, and obesity. There are a number of ques-
tions regarding dietary fructose and its impact on lipid
and carbohydrate metabolism and energy homeostasis
that need further study. These are outlined below.
Fructose Consumption
● How much fructose is actually being consumed by the
population as a whole and by specific segments of the
population, particularly children and adolescents? Ex-
isting food disappearance and current survey data have
limitations. New surveys should incorporate tools spe-
cifically designed to assess the consumption of fructose
and fructose-containing foods.
Fructose and Lipids
● What are the mechanisms underlying the effects of
fructose to induce postprandial hypertriglyceridemia
and increase ApoB levels? Are the increases primar-
ily due to increased VLDL production, decreased
clearance, or a combination of the two processes?
Stable isotope studies could provide valuable new
information.
● What is the impact of fructose consumption on lipid
profiles in men and women with the metabolic
syndrome, i.e., visceral obesity, insulin resistance,
existing dyslipidemia, elevated markers of inflam-
mation, and hypertension?
● What is the atherogenic potential of fructose-in-
duced hyperlipidemia? In addition to increasing
ApoB, does fructose have effects on lipoprotein
particle size distribution (e.g., small, dense LDL)
and on other cardiovascular risk factors such as
plasminogen activator inhibitor-1, remnant lipopro-
teins, and decreased adiponectin production?
Fructose and Insulin Resistance
● What is the impact of chronically consuming a diet
high in fructose on insulin action and carbohydrate
metabolism, as assessed by validated and sensitive
methods such as mathematical modeling analysis of
fast-sampled IV glucose tolerance test data and
hyperinsulinemic clamps? Such studies are particu-
larly important in subjects with preexisting meta-
bolic disease such as those exhibiting components of
the metabolic syndrome.
● Does consuming a high-fructose diet lead to in-
creased levels of inflammatory markers implicated
in insulin resistance and cardiovascular risk, includ-
ing but not limited to C-reactive protein, tumor
necrosis factor-alpha, interleukin-6, and monocyte
chemoattractant protein-1, as well as markers of
oxidative stress?
● Can long-term fructose consumption lead to insulin
resistance by increasing lipid deposition in liver and
skeletal muscle (intramyocellular lipid)?
Fructose and Diabetes
● What levels of fructose in the diet are safe and
potentially beneficial in the diet of patients with
diabetes and at what level does fructose consump-
tion have potentially detrimental effects on lipids,
insulin action, -cell function, and/or energy bal-
ance/weight gain?
● What is the impact of consuming high levels of
dietary fructose on protein fructosylation, the polyol
pathway, and oxidative stress, all of which could
potentially contribute to the long-term complication
of diabetes including retinopathy, neuropathy, and
renal disease?
Fructose and Energy Homeostasis
● Does long-term consumption of a high-fructose diet
lead to increased energy intake and weight gain, and
how is this related to the endocrine signals involved
in the regulation of energy homeostasis?
● Does the source/formulation of dietary fructose,
e.g., sucrose versus HFCS-55, influence the short-
term endocrine and metabolic effects of fructose and
its long-term impact on energy homeostasis?
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